[Ip-health] MSF responds to TB Alliance announcement of the Nix-TB clinical trial

Michelle French Michelle.French at newyork.msf.org
Thu May 14 09:40:12 PDT 2015

MSF responds to TB Alliance announcement of the Nix-TB clinical trial 

On 13 May, TB Alliance announced the start of its Nix-TB (New 
Investigational Drugs for XDR-TB) clinical trial, the first to test a new 
all-oral regimen for extensively drug-resistant tuberculosis (XDR-TB): 
Background info (statement follows): 
Médecins Sans Frontières (MSF) provides TB treatment in about 30 countries 
and is one of the largest non-governmental agencies treating 
drug-resistant TB.  XDR-TB is the deadliest form of drug-resistant TB and 
better treatments are urgently needed.  People who manage to access and 
endure the debilitating side effects of the required two-year treatment 
regimen, including 8 months of painful daily injections, still have less 
than a 20% chance of surviving the disease. Globally it is thought that 
XDR-TB affects nearly 50,000 people in more than 100 countries, with some 
regions very severely affected. 

Faced with these realities on the ground, MSF has long been working on a 
number of fronts to deliver improved treatment regimens for drug-resistant 
TB, from advocating on principles for designing future regimens for 
multidrug-resistant tuberculosis (MDR-TB) and to the patient-centered “
Test Me, Treat Me” DR-TB Manifesto that called for more effective, 
tolerable, shorter and affordable DR-TB treatments.  MSF is also working 
to implement a new drug development initiative, the ‘3P project’, that 
aims to rapidly deliver affordable new TB treatment regimens that can 
ultimately cure all forms of TB.  In March 2015, MSF announced its 
participation in the ‘endTB project’, which will provide access to two new 
anti-TB drugs (bedaquiline and delamanid) for 2,600 MDR-TB patients in 16 
countries and conduct clinical trials for new regimens to treat multi-drug 
resistant TB. 

Statement by Dr. Bern-Thomas Nyang'wa, Project Manager and TB Specialist, 
Médecins Sans Frontières Manson Unit: 

“MSF welcomes the start of the Nix-TB clinical trial as a first step 
towards delivering more tolerable, effective and shorter treatments that 
our patients and doctors have long called for.  It’s true that the 
approval of new TB drugs is not sufficient progress in itself – the true 
impact of these new drugs won’t be realized until they are incorporated 
into treatment regimens that are proven effective and made accessible to 
people who need them.  In the meantime, patients without other treatment 
options should be given access to new and promising drugs through early 
access programs. 

Optimal treatment regimens shouldn’t contain injectable drugs, shouldn’t 
cause deafness, psychosis or other debilitating side effects, and should 
offer patients real hope of being cured. While these issues are most acute 
for XDR-TB patients, we hope that Nix-TB will be able to quickly expand to 
include MDR-TB patients, who are desperately in need of better treatment 
options as well.” 


Michelle French
Sr. Communications Manager, MSF Access Campaign
Doctors Without Borders\Médecins Sans Frontières (MSF)
Office: +1.212.763.5735 | Mobile: +1.646.552.4600
michelle.french at newyork.msf.org | Skype: michellejfrench
www.msfaccess.org | twitter.com/MSF_access | www.facebook.com/MSFaccess

More information about the Ip-health mailing list